A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis

•FluBu and CyTBI are common myeloablative conditioning regimens for HSCT.•Overall survival is superior with FluBu for hematologic malignancies.•Nonrelapse mortality and grade II to IV aGVHD are better with FluBu, while relapse is similar.•Outcomes with FluBu are better at age

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biology of blood and marrow transplantation 2018-08, Vol.24 (8), p.1733-1740
Hauptverfasser:	Gooptu, Mahasweta, Kim, Haesook T., Ho, Vincent T., Alyea, Edwin P., Koreth, John, Armand, Philippe, Ritz, Jerome, Nikiforow, Sarah, Glotzbecker, Brett E., Nageshwar, Prashant, Soiffer, Robert J., Antin, Joseph H., Cutler, Corey S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Allogeneic transplant Busulfan - therapeutic use Cohort Studies Cyclophosphamide - therapeutic use Female Fludarabine Graft vs Host Disease - mortality Graft-versus-host disease Hematologic Neoplasms - mortality Hematologic Neoplasms - therapy Hematopoietic Stem Cell Transplantation - methods Hematopoietic Stem Cell Transplantation - mortality Humans Leukemia, Myeloid, Acute Male Middle Aged Myeloablative Myeloablative Agonists - therapeutic use Myelodysplastic Syndromes Recurrence Reduced toxicity Retrospective Studies Survival Analysis Transplantation Conditioning - methods Transplantation Conditioning - mortality Vidarabine - analogs & derivatives Vidarabine - therapeutic use Whole-Body Irradiation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•FluBu and CyTBI are common myeloablative conditioning regimens for HSCT.•Overall survival is superior with FluBu for hematologic malignancies.•Nonrelapse mortality and grade II to IV aGVHD are better with FluBu, while relapse is similar.•Outcomes with FluBu are better at age
ISSN:	1083-8791 1523-6536
DOI:	10.1016/j.bbmt.2018.03.011